Drugs / RSC-1255
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04678648 | Mar 2021 → Dec 2026 expected | colorectal cancer, glioblastoma, lung cancer, malignant pancreatic neoplasm | RasCal Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSC-1255 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04678648 ↗ |
| Action | Inhibit | “RSC-1255 is an orally bioavailable, small-molecule direct pan-mutant and wild-type RAS inhibitor.” NCT04678648 ↗ |
| Modality | Small molecule | “RSC-1255 is an orally bioavailable, small-molecule direct pan-mutant and wild-type RAS inhibitor.” NCT04678648 ↗ |
| Route | Oral | “RSC-1255 is administered orally twice daily” NCT04678648 ↗ |